ES2262626T3 - Inhibidores de farnesil proteina transferasa para tratar cancer de mama. - Google Patents

Inhibidores de farnesil proteina transferasa para tratar cancer de mama.

Info

Publication number
ES2262626T3
ES2262626T3 ES01905717T ES01905717T ES2262626T3 ES 2262626 T3 ES2262626 T3 ES 2262626T3 ES 01905717 T ES01905717 T ES 01905717T ES 01905717 T ES01905717 T ES 01905717T ES 2262626 T3 ES2262626 T3 ES 2262626T3
Authority
ES
Spain
Prior art keywords
methyl
breast cancer
inhibitor
pharmaceutical composition
farnesyl protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01905717T
Other languages
English (en)
Spanish (es)
Inventor
Peter Albert Janssen Pharmaceutica N.V PALMER
Ivan David Horak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2262626T3 publication Critical patent/ES2262626T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES01905717T 2000-02-04 2001-02-01 Inhibidores de farnesil proteina transferasa para tratar cancer de mama. Expired - Lifetime ES2262626T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00200373 2000-02-04
EP00200373 2000-02-04

Publications (1)

Publication Number Publication Date
ES2262626T3 true ES2262626T3 (es) 2006-12-01

Family

ID=8170976

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01905717T Expired - Lifetime ES2262626T3 (es) 2000-02-04 2001-02-01 Inhibidores de farnesil proteina transferasa para tratar cancer de mama.

Country Status (13)

Country Link
US (4) US20030027839A1 (cg-RX-API-DMAC10.html)
EP (1) EP1255537B1 (cg-RX-API-DMAC10.html)
JP (1) JP5491681B2 (cg-RX-API-DMAC10.html)
AT (1) ATE323474T1 (cg-RX-API-DMAC10.html)
AU (1) AU2001233726A1 (cg-RX-API-DMAC10.html)
CA (1) CA2396865C (cg-RX-API-DMAC10.html)
CY (1) CY1105477T1 (cg-RX-API-DMAC10.html)
DE (1) DE60118889T2 (cg-RX-API-DMAC10.html)
DK (1) DK1255537T3 (cg-RX-API-DMAC10.html)
ES (1) ES2262626T3 (cg-RX-API-DMAC10.html)
PT (1) PT1255537E (cg-RX-API-DMAC10.html)
SI (1) SI1255537T1 (cg-RX-API-DMAC10.html)
WO (1) WO2001056552A2 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
WO2002064142A1 (en) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with antiestrogen agents
WO2003047697A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer
US7102251B2 (en) * 2003-08-22 2006-09-05 Distributed Power, Inc. Bi-directional multi-port inverter with high frequency link transformer
BRPI0416316A (pt) * 2003-11-06 2007-01-09 Schering Corp combinação de um inibidor da farnesil transferase com um agente anti-hormonal para o tratamento de cáncer de mama
JP2007516258A (ja) 2003-12-12 2007-06-21 ワイス 心臓血管の疾患治療に有用なキノリン誘導体
CA2559221A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20050288298A1 (en) * 2004-03-18 2005-12-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2559285A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
AU2006331542A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
AU2009313927A1 (en) * 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2288195B1 (en) * 2009-08-20 2019-10-23 Samsung Electronics Co., Ltd. Method and apparatus for operating a base station in a wireless communication system
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
HK1213887A1 (zh) 2012-10-16 2016-07-15 Janssen Pharmaceutica N.V. RORγt的苯基连接的喹啉基调节剂
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10471055B2 (en) 2015-08-17 2019-11-12 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
HRP20210544T1 (hr) 2016-11-03 2021-08-20 Kura Oncology, Inc. Inhibitori farneziltransferaze za uporabu u liječenju raka

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635966T2 (de) * 1995-12-08 2006-11-30 Janssen Pharmaceutica N.V. (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US5994364A (en) * 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
SK146199A3 (en) * 1997-04-25 2000-06-12 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
US5925639A (en) * 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US5852034A (en) * 1997-06-17 1998-12-22 Schering Corporation Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6410534B1 (en) * 1998-07-02 2002-06-25 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ID26987A (id) * 1998-07-06 2001-02-22 Janssen Pharmaceutica Nv Inhibitor-inhibitor transferase protein farnesil dengan sifat-sifat peka terhadap sinar radiasi in vivo
CA2341739C (en) * 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
PT1140935E (pt) * 1998-12-23 2003-10-31 Janssen Pharmaceutica Nv Derivados da quinolina 1,2-ciclizada
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
JP2003523381A (ja) * 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
AU2001244166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
US20020022633A1 (en) * 2000-06-30 2002-02-21 Williams Theresa M. Inhibitors of prenyl-protein transferase

Also Published As

Publication number Publication date
US20030027839A1 (en) 2003-02-06
ATE323474T1 (de) 2006-05-15
JP5491681B2 (ja) 2014-05-14
US20040192726A1 (en) 2004-09-30
DE60118889T2 (de) 2006-11-30
WO2001056552A3 (en) 2002-04-25
EP1255537B1 (en) 2006-04-19
SI1255537T1 (sl) 2006-10-31
US20110098318A1 (en) 2011-04-28
US20090018164A1 (en) 2009-01-15
WO2001056552A2 (en) 2001-08-09
JP2003521509A (ja) 2003-07-15
CA2396865C (en) 2009-04-14
DE60118889D1 (de) 2006-05-24
CA2396865A1 (en) 2001-08-09
EP1255537A2 (en) 2002-11-13
PT1255537E (pt) 2006-09-29
DK1255537T3 (da) 2006-08-21
AU2001233726A1 (en) 2001-08-14
CY1105477T1 (el) 2010-04-28

Similar Documents

Publication Publication Date Title
EP1255537B1 (en) Farnesyl protein transferase inhibitors for treating breast cancer
US7314862B2 (en) Antitumor agent
EP1002556A2 (en) Use of MMP inhibitors
ES2318000T3 (es) Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos.
JP2001520189A (ja) 抗腫瘍剤の毒性を低減するための調合物及び方法
RU2401662C2 (ru) Фармацевтические композиции и способы лечения рака и его метастазов
CN101808636B (zh) 黑色素瘤的治疗
WO1994016687A1 (en) Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth
CN116077631A (zh) 涉及粘液素的疾病治疗
JP2010031043A (ja) ガンの治療
RU2334517C2 (ru) Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство
KR19990082064A (ko) 피페라진 옥시란 유도체를 사용하여 신생 세포의 사멸을유도하는 방법
KR102002581B1 (ko) 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
EP3829623A1 (en) Methods for reducing abnormal scar formation
JP2004536022A (ja) エストロゲン依存性疾患のための組み合わせ療法
EP3010508B1 (en) Combination of ro5503781, capecitabine and oxaliplatin for cancer therapy
CN115869316A (zh) 伊斯平斯在制备联合抗乳腺癌药物方面的用途
EP3010513B1 (en) Combination of ro5503781 and capecitabine for cancer therapy
JP2003509383A (ja) 化学療法を強化し、充実性腫瘍を治療する方法
CN120091822A (zh) 用于肿瘤血管阻断的药物组合物
CA2120234A1 (en) 2-aminopropan-1,3-diol chemotherapeutic agents
KR20100131457A (ko) 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제
HK1229695A1 (en) Novel methods for treating cancer
HK1128234B (en) Combination comprising combretastatin and anticancer agents
HK1128234A1 (en) Combination comprising combretastatin and anticancer agents